← Back to Search

Vibrotactile Stimulation for Stroke Recovery

N/A
Recruiting
Led By Leigh A Mrotek, PhD
Research Sponsored by Marquette University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A minimal active wrist extension of 5°
Mild-to-moderate motor impairment as assessed using the upper extremity (UE) portion of the Fugl-Meyer Motor Assessment (FM); i.e., UE-FM score between 28 and 50 (inclusive) out of a possible 66
Must not have
Subjects who are currently using or under the influence of aminoglycoside antibiotics, curare-like agents, or other agents that may interfere with neuromuscular function
Malignant or benign intra-axial neoplasms
Timeline
Screening 3 weeks
Treatment Varies
Follow Up across experimental sessions spanning a typical time frame of 4 to 6 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether adding vibrotactile stimulation can help improve arm function for people who have lost proprioception after a stroke.

Who is the study for?
This trial is for stroke survivors with mild-to-moderate arm impairment, who can feel touch in the affected arm or thigh and have a minimal ability to extend their wrist. They must be at least 6 months post-stroke from an MCA event, able to consent and follow instructions, and have specific proprioceptive deficits. People with bleeding disorders, muscle diseases like ALS or myasthenia gravis, epilepsy, severe psychiatric conditions, pacemakers or significant heart issues cannot join.
What is being tested?
The study tests if vibrotactile stimulation—a type of sensory feedback—can help improve arm function after stroke. Thirty participants will try this method while doing tasks like reaching out or simulating drinking from a glass to see if it enhances motor control.
What are the potential side effects?
While not explicitly stated in the provided information, typical side effects of vibrotactile stimulation may include skin irritation where the device is applied and potential discomfort due to vibration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can slightly bend my wrist upwards.
Select...
I have mild-to-moderate difficulty moving my arms.
Select...
I have trouble sensing joint movement in my elbow on the side of my body opposite to my stronger arm.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not currently using drugs that affect muscle function.
Select...
I have a tumor inside my brain.
Select...
My muscles in the testing area are very weak or have shrunk significantly.
Select...
I have a systemic infection.
Select...
I can understand and follow detailed instructions.
Select...
I have a heart pacemaker, irregular heartbeat, or serious heart/lung issues.
Select...
I have a bleeding disorder.
Select...
I do not have conditions like myasthenia gravis or ALS that affect muscle control.
Select...
I have stiff joints or have had tendon surgery in my affected limb.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~across experimental sessions spanning a typical time frame of 4 to 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and across experimental sessions spanning a typical time frame of 4 to 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Root Mean Square Kinematic Error

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Stroke Cohort - Whole Task TrainingExperimental Treatment1 Intervention
Aim2 intervention: Vibrotactile stimulation. Training on only the more complex reaching task using vibrotactile feedback to guide performance
Group II: Stroke Cohort - Progressive TrainingExperimental Treatment1 Intervention
Aim 1 intervention: Vibrotactile stimulation. Progressive training from simple to more complex reaching task using vibrotactile feedback to guide performance
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vibrotactile stimulation
2017
N/A
~170

Find a Location

Who is running the clinical trial?

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,055 Previous Clinical Trials
2,731,864 Total Patients Enrolled
84 Trials studying Stroke
5,769 Patients Enrolled for Stroke
Marquette UniversityLead Sponsor
63 Previous Clinical Trials
200,419 Total Patients Enrolled
7 Trials studying Stroke
302 Patients Enrolled for Stroke
Medical College of WisconsinOTHER
631 Previous Clinical Trials
1,181,928 Total Patients Enrolled
17 Trials studying Stroke
1,400 Patients Enrolled for Stroke

Media Library

Vibrotactile stimulation Clinical Trial Eligibility Overview. Trial Name: NCT03298243 — N/A
Stroke Research Study Groups: Stroke Cohort - Whole Task Training, Stroke Cohort - Progressive Training
Stroke Clinical Trial 2023: Vibrotactile stimulation Highlights & Side Effects. Trial Name: NCT03298243 — N/A
Vibrotactile stimulation 2023 Treatment Timeline for Medical Study. Trial Name: NCT03298243 — N/A
~8 spots leftby May 2025